Immuneering Corp (IMRX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US45254E1073
Immuneering Corp financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -59.38 m USD |
| EBIT | -59.06 m USD |
| Net income | -56.02 m USD |
| Diluted EPS – continuing operations | -1.27 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Immuneering Corp
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
More stocks
- F&M BANK CORP (FMBM)
- Traeger, Inc. (COOK)
- Sangoma Technologies Corp (STC.TO)
- Magatouch Co.,Ltd. (446540.KQ)
- Stars Microelectronics (Thailand) PCL (SMT.BK)
- Gesco (GSC1.DE)
- Foraco International SA (FAR.TO)
- Eagle Bancorp Montana, Inc. (EBMT)
- Xponential Fitness, Inc. (XPOF)
- Hushan Autoparts Inc. (7736.TW)
- EDAP TMS SA (FOCL)
- Guanajuato Silver Company Ltd (GSVR.V)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.